• Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation.
• First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies to allow administration of gene therapy.

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results | Hansa Biopharma

(www.hansabiopharma.com)